Dobs Adrian S, Nguyen Tam, Pace Cindy, Roberts Carla P
Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
J Clin Endocrinol Metab. 2002 Apr;87(4):1509-16. doi: 10.1210/jcem.87.4.8362.
Menopause is associated with decreased lean body mass and increased fat due to aging and declining hormone secretion. Estrogens or estrogen-progestins have been used to alleviate vasomotor symptoms. However, estrogen-androgen (E/A) therapy is also used for vasomotor symptom relief and has been shown to increase lean body mass while decreasing fat mass. The objective of this 16-wk, double-blind, randomized, parallel group clinical trial was to compare esterified estrogen plus methyltestosterone (1.25 mg estrogen + 2.5 mg methyltestosterone/d; E/A group) vs. esterified estrogen alone (1.25 mg/d; E group) on body composition. Forty postmenopausal women (mean age, 57 yr) participated. Compared with estrogen treatment alone, women in the E/A group increased their total lean body mass and reduced their percentage fat for all body parts (P < 0.05). After E/A treatment, there were statistically significant increases in lean body mass by 1.232 kg [0.181 +/- 0.004, 0.81 +/- 0.057, and 0.24 +/- 0.009 kg in the upper body (P = 0.021), trunk (P = 0.001), and lower body (P = 0.047), respectively]. In the E group, the increase was 0.31 +/- 0.004, 0.021 +/- 0.03, and 0.056 +/- 0.05 kg in the upper body, trunk, and lower body, respectively. In the E/A group, body fat was reduced by 0.90 kg (P = 0.18 for the trunk only), and percentage body fat declined by 7.4% (P < or = 0.05 for all body parts). Lower body strength increased by 23.1 kg (51 lb) in the E/A group vs. only 11 kg (24.25 lb) in the E group (P = 0.002 between groups). A statistically significant increase in weight (2.7 +/- 5.1 vs. 0.1 +/- 4.6 lb; P < 0.05) was observed in the E/A group compared with the E group. When subjects were given self-reporting questionnaires, more improvement was noted in sexual functioning and quality of life in the E/A group when compared with patients receiving E alone. There were no noteworthy side effects. In conclusion, E/A replacement therapy can improve body composition, lower-body muscle strength, quality of life, and sexual functioning in postmenopausal women.
由于衰老和激素分泌减少,更年期与瘦体重下降和脂肪增加有关。雌激素或雌激素 - 孕激素已被用于缓解血管舒缩症状。然而,雌激素 - 雄激素(E/A)疗法也用于缓解血管舒缩症状,并且已显示可增加瘦体重同时减少脂肪量。这项为期16周的双盲、随机、平行组临床试验的目的是比较酯化雌激素加甲基睾酮(1.25毫克雌激素 + 2.5毫克甲基睾酮/天;E/A组)与单独使用酯化雌激素(1.25毫克/天;E组)对身体成分的影响。40名绝经后女性(平均年龄57岁)参与了试验。与单独使用雌激素治疗相比,E/A组女性的总瘦体重增加,所有身体部位的脂肪百分比降低(P < 0.05)。E/A治疗后,瘦体重有统计学显著增加,上身增加1.232千克[分别为0.181 +/- 0.004、0.81 +/- 0.057和0.24 +/- 0.009千克(P = 0.021)]、躯干增加(P = 0.001)、下身增加(P = 0.047)。在E组中,上身、躯干和下身分别增加0.31 +/- 0.004、0.021 +/- 0.03和0.056 +/- 0.05千克。在E/A组中,身体脂肪减少了0.90千克(仅躯干P = 0.18),身体脂肪百分比下降了7.4%(所有身体部位P <或= 0.05)。E/A组下身力量增加了23.1千克(51磅),而E组仅增加了11千克(24.25磅)(两组之间P = 0.002)。与E组相比,E/A组体重有统计学显著增加(2.7 +/- 5.1对0.1 +/- 4.6磅;P < 0.05)。当给受试者自我报告问卷时,与仅接受E治疗的患者相比,E/A组在性功能和生活质量方面有更多改善。没有值得注意的副作用。总之,E/A替代疗法可以改善绝经后女性的身体成分、下身肌肉力量、生活质量和性功能。